FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3091522916> ?p ?o ?g. }

• W3091522916 endingPage "68" @default.
• W3091522916 startingPage "61" @default.
• W3091522916 abstract "H3F3A mutations and the expression of glycine 34 to tryptophan (G34W) mutants in giant cell tumors of bone (GCTBs) and other bone tumors were detected to compare H3F3A mutation types and the expression of G34W-mutant protein in order to provide a theoretical basis for using H3F3A mutations as a diagnostic and differential-diagnostic tool for GCTBs. A total of 366 bone tumor cases were investigated. The cases involved 215 men and 151 women, whose median age was 29 years (3-84). The cases included GCTB (n=180), recurrent GCTB (n=19), GCTB with lung metastasis (n=5), pediatric GCTB (n=15), primary malignant GCTB (n=5), chondroblastoma (CB, n=61), chondrosarcoma grade II (n=15), dedifferentiated chondrosarcoma (n=17), chondromyxoid fibroma (n=9), aneurysmal bone cyst (n=9), nonossifying fibroma (n=9), osteosarcoma (n=16), and undifferentiated sarcoma (n=6). Sanger DNA sequencing analysis was used to detect H3F3A mutations. Immunohistochemistry was used to assess the expression of the G34W-mutated protein in these bone tumors. DNA sequencing results revealed H3F3A mutations in 95.00% of GCTBs (171/180), including glycine 34 to tryptophan (G34W, 163/180, 90.56%), glycine 34 to leucine (G34L, 3/180, 1.67%), glycine 34 to valine (G34V, 3/180, 1.67%), and glycine 34 to arginine (G34R, 2/180, 1.11%). Recurrent GCTBs mostly had the H3F3A G34W mutation (18/19, 94.74%), and GCTBs with lung metastasis all had the H3F3A G34W mutation (5/5, 100%). Pediatric GCTBs had a mutation rate of 93.33% (14/15), including one case with G34L. Four cases of primary malignant GCTB showed the H3F3A G34W mutation (4/5, 80.00%), and the classical GCTB component and malignant component showed consistent mutation types. Immunohistochemistry showed that GCTBs harboring G34W also expressed the mutant protein in tumor cell nuclei. Furthermore, one case of GCTB and one case of recurrent GCTB showed positive G34W immunostaining results despite being negative for the genetic mutation. Other bone tumors all showed wild-type expression in both DNA sequencing and immunohistochemistry. Our large-sample DNA sequencing analysis detected four different forms of mutations in GCTBs, including three rare mutation forms. The most common mutation of H3F3A was G34W, which was in accordance with the expression of G34W in GCTBs detected by immunohistochemistry. Although DNA sequencing analysis detected rare mutation types of H3F3A, false-negative results were also present due to the small number of cells in the samples. Detection of the most common (G34W) mutant protein by immunohistochemistry was more convenient. Given the high prevalence of these driver mutations, the detection of H3F3A mutant proteins can assist in the diagnosis of GCTB and its differential diagnosis from other bone tumors." @default.
• W3091522916 created "2020-10-08" @default.
• W3091522916 creator A5022728544 @default.
• W3091522916 creator A5023560466 @default.
• W3091522916 creator A5027377891 @default.
• W3091522916 creator A5031157158 @default.
• W3091522916 creator A5076327917 @default.
• W3091522916 creator A5078949281 @default.
• W3091522916 date "2021-01-01" @default.
• W3091522916 modified "2023-10-01" @default.
• W3091522916 title "H3F3A G34 mutation DNA sequencing and G34W immunohistochemistry analysis in 366 cases of giant cell tumors of bone and other bone tumors." @default.
• W3091522916 cites W1960585793 @default.
• W3091522916 cites W197700271 @default.
• W3091522916 cites W2029691061 @default.
• W3091522916 cites W2045165255 @default.
• W3091522916 cites W2056155872 @default.
• W3091522916 cites W2063068656 @default.
• W3091522916 cites W2067953553 @default.
• W3091522916 cites W2076248496 @default.
• W3091522916 cites W2100757960 @default.
• W3091522916 cites W2116063037 @default.
• W3091522916 cites W2155697005 @default.
• W3091522916 cites W2323861490 @default.
• W3091522916 cites W2419895660 @default.
• W3091522916 cites W2510111484 @default.
• W3091522916 cites W2569400120 @default.
• W3091522916 cites W2588291630 @default.
• W3091522916 cites W2613199308 @default.
• W3091522916 cites W2631252908 @default.
• W3091522916 cites W2775214577 @default.
• W3091522916 cites W2793100059 @default.
• W3091522916 doi "https://doi.org/10.14670/hh-18-264" @default.
• W3091522916 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33021329" @default.
• W3091522916 hasPublicationYear "2021" @default.
• W3091522916 type Work @default.
• W3091522916 sameAs 3091522916 @default.
• W3091522916 citedByCount "11" @default.
• W3091522916 countsByYear W30915229162022 @default.
• W3091522916 countsByYear W30915229162023 @default.
• W3091522916 crossrefType "journal-article" @default.
• W3091522916 hasAuthorship W3091522916A5022728544 @default.
• W3091522916 hasAuthorship W3091522916A5023560466 @default.
• W3091522916 hasAuthorship W3091522916A5027377891 @default.
• W3091522916 hasAuthorship W3091522916A5031157158 @default.
• W3091522916 hasAuthorship W3091522916A5076327917 @default.
• W3091522916 hasAuthorship W3091522916A5078949281 @default.
• W3091522916 hasConcept C104317684 @default.
• W3091522916 hasConcept C121608353 @default.
• W3091522916 hasConcept C142724271 @default.
• W3091522916 hasConcept C153911025 @default.
• W3091522916 hasConcept C2776302905 @default.
• W3091522916 hasConcept C2777062278 @default.
• W3091522916 hasConcept C2777190185 @default.
• W3091522916 hasConcept C2777194990 @default.
• W3091522916 hasConcept C2777783956 @default.
• W3091522916 hasConcept C2779013556 @default.
• W3091522916 hasConcept C2780686914 @default.
• W3091522916 hasConcept C2781156865 @default.
• W3091522916 hasConcept C501734568 @default.
• W3091522916 hasConcept C502942594 @default.
• W3091522916 hasConcept C54355233 @default.
• W3091522916 hasConcept C71924100 @default.
• W3091522916 hasConcept C77076574 @default.
• W3091522916 hasConcept C86803240 @default.
• W3091522916 hasConceptScore W3091522916C104317684 @default.
• W3091522916 hasConceptScore W3091522916C121608353 @default.
• W3091522916 hasConceptScore W3091522916C142724271 @default.
• W3091522916 hasConceptScore W3091522916C153911025 @default.
• W3091522916 hasConceptScore W3091522916C2776302905 @default.
• W3091522916 hasConceptScore W3091522916C2777062278 @default.
• W3091522916 hasConceptScore W3091522916C2777190185 @default.
• W3091522916 hasConceptScore W3091522916C2777194990 @default.
• W3091522916 hasConceptScore W3091522916C2777783956 @default.
• W3091522916 hasConceptScore W3091522916C2779013556 @default.
• W3091522916 hasConceptScore W3091522916C2780686914 @default.
• W3091522916 hasConceptScore W3091522916C2781156865 @default.
• W3091522916 hasConceptScore W3091522916C501734568 @default.
• W3091522916 hasConceptScore W3091522916C502942594 @default.
• W3091522916 hasConceptScore W3091522916C54355233 @default.
• W3091522916 hasConceptScore W3091522916C71924100 @default.
• W3091522916 hasConceptScore W3091522916C77076574 @default.
• W3091522916 hasConceptScore W3091522916C86803240 @default.
• W3091522916 hasIssue "1" @default.
• W3091522916 hasLocation W30915229161 @default.
• W3091522916 hasOpenAccess W3091522916 @default.
• W3091522916 hasPrimaryLocation W30915229161 @default.
• W3091522916 hasRelatedWork W151022074 @default.
• W3091522916 hasRelatedWork W1512931626 @default.
• W3091522916 hasRelatedWork W1969543467 @default.
• W3091522916 hasRelatedWork W1980015303 @default.
• W3091522916 hasRelatedWork W1992015393 @default.
• W3091522916 hasRelatedWork W2031034417 @default.
• W3091522916 hasRelatedWork W2060900142 @default.
• W3091522916 hasRelatedWork W2079322026 @default.
• W3091522916 hasRelatedWork W2118735245 @default.
• W3091522916 hasRelatedWork W2120711389 @default.
• W3091522916 hasRelatedWork W2188605968 @default.
• W3091522916 hasRelatedWork W2254176434 @default.

• next